Chih‐Hung Hsu

16.2k total citations · 2 hit papers
303 papers, 7.3k citations indexed

About

Chih‐Hung Hsu is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Chih‐Hung Hsu has authored 303 papers receiving a total of 7.3k indexed citations (citations by other indexed papers that have themselves been cited), including 142 papers in Oncology, 99 papers in Surgery and 87 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Chih‐Hung Hsu's work include Hepatocellular Carcinoma Treatment and Prognosis (76 papers), Cancer Immunotherapy and Biomarkers (62 papers) and Esophageal Cancer Research and Treatment (57 papers). Chih‐Hung Hsu is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (76 papers), Cancer Immunotherapy and Biomarkers (62 papers) and Esophageal Cancer Research and Treatment (57 papers). Chih‐Hung Hsu collaborates with scholars based in Taiwan, United States and Japan. Chih‐Hung Hsu's co-authors include Ann‐Lii Cheng, Yu‐Yun Shao, Chiun Hsu, Li‐Chun Lu, Pei‐Jer Chen, Ying‐Chun Shen, Kun‐Huei Yeh, Wen-Chi Feng, Zhong‐Zhe Lin and Kuen‐Feng Chen and has published in prestigious journals such as Journal of Biological Chemistry, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Chih‐Hung Hsu

286 papers receiving 7.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial

2019 751 citations Yuichiro� Doki, Chih‐Hung Hsu et al. profile →
Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma

2022 342 citations Chih‐Hung Hsu et al. profile →

Peers

Countries citing papers authored by Chih‐Hung Hsu

Since Specialization

Citations

This map shows the geographic impact of Chih‐Hung Hsu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chih‐Hung Hsu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chih‐Hung Hsu more than expected).

Fields of papers citing papers by Chih‐Hung Hsu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chih‐Hung Hsu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chih‐Hung Hsu. The network helps show where Chih‐Hung Hsu may publish in the future.

Co-authorship network of co-authors of Chih‐Hung Hsu

This figure shows the co-authorship network connecting the top 25 collaborators of Chih‐Hung Hsu. A scholar is included among the top collaborators of Chih‐Hung Hsu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chih‐Hung Hsu. Chih‐Hung Hsu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Clinical outcome analysis of different first‑ and second‑generation EGFR‑tyrosine kinase inhibitors in untreated patients with EGFR‑mutated non‑small cell lung cancer with baseline brain metastasis 2025 ·Oncology Letters ·Chih‐Hung Hsu, Li‐Chung Chiu, (unknown), (unknown), Chih‐Hsi S. Kuo, (unknown), (unknown), Chin‐Chou Wang, Cheng‐Ta Yang, Ping‐Chih Hsu	1
2	Effect of chronic kidney disease on survival in patients with chronic obstructive pulmonary disease 2025 ·Respiratory Medicine ·Chih‐Hung Hsu, (unknown), Ting‐Yu Lin, Shih-Wei Huang, (unknown), (unknown), (unknown), Haoming Wu, (unknown), (unknown), (unknown), Shu‐Min Lin	0
3	NOTCH1 Mutation and Survival Analysis of Tislelizumab in Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Biomarker Analysis From the Randomized, Phase III, RATIONALE-302 Trial 2025 ·Journal of Clinical Oncology ·(unknown), Wenting Du, Xi Jiao, Yanni Wang, Jingwen Shi, Yang Shi, Yongqian Shu, Zuoxing Niu, Hiroki Hara, Jun Wu, Chih‐Hung Hsu, Eric Van Cutsem, Malcolm V. Brock, Zhang Zhang, Ningning Ding, Yun Zhang, (unknown), Lin Shen	2
4	Cyclin dependent kinase 9 inhibition reduced programmed death-ligand 1 expression and improved treatment efficacy in hepatocellular carcinoma 2024 ·Heliyon ·Yu‐Yun Shao, Min‐Shu Hsieh, Yi‐Hsuan Lee, (unknown), (unknown), Hanyu Wang, Ann‐Lii Cheng, Chih‐Hung Hsu	1
5	Phase 1/2 study of NGM707, an ILT2/ILT4 dual antagonist antibody, in advanced solid tumors: Interim results from dose-escalation. 2024 ·Journal of Clinical Oncology ·Judy S. Wang, David Sommerhalder, Manish Sharma, William J. Edenfield, Kartik Sehgal, Do‐Youn Oh, Yixing Jiang, Joel Michalski, Jeeyun Lee, Hans J. Hammers, Li‐Yuan Bai, Chih‐Hung Hsu, (unknown), Kefei Zhou, Lisa K. Blum, (unknown), (unknown), Hsiao D. Lieu, Vladimir Hanes, Aung Naing	2
6	A phase II, multi-center, open-label study to evaluate the safety and efficacy of YH003 in combination with toripalimab (anti-PD-1 mAb) in patients with unresectable/metastatic pancreatic ductal adenocarcinoma (PDAC). 2024 ·Journal of Clinical Oncology ·(unknown), Lin Shen, Sumitra Ananda, Dan Cao, Catherine Han, Jermaine Coward, (unknown), Wei Li, (unknown), Chih‐Hung Hsu, Adnan Nagrial, (unknown), Vinod Ganju, Xiaobing Chen, Deirdre Jill Cohen, Rajiv Kumar, Li-Yuan Bai, Ying Yuan, (unknown)	1
7	Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): 45-month (mo) follow-up from CheckMate 648. 2024 ·Journal of Clinical Oncology ·Ian Chau, Jaffer A. Ajani, Yuko Kitagawa, Jianming Xu, Lucjan Wyrwicz, Satoru Motoyama, Takashi Ogata, Hisato Kawakami, Chih‐Hung Hsu, Antoine Adenis, Farid El Hajbi, Maria Di Bartolomeo, Maria Ignez Braghiroli, Eva Holtved, Mariela A. Blum Murphy, Raheel Nathani, Nan Hu, Yasuhiro Matsumura, (unknown), Yuichiro� Doki	0
8	EP.11E.01 Immune-Related Myasthenia Gravis in Patients with NSCLC: A Case Series 2024 ·Journal of Thoracic Oncology ·Yuan‐Huan Kang, Ming‐Hsien Lin, Chih‐Yuan Wang, Chih‐Hung Hsu, Yaling Jiang, Chao-Feng Chen	0
9	Abstract 2211: The prognostic role of tertiary lymphoid structure (TLS) in locally advanced esophageal squamous cell carcinoma (ESCC) 2023 ·Cancer Research ·(unknown), Cher‐Wei Liang, (unknown), (unknown), Chia‐Chi Lin, Jang‐Ming Lee, Yin‐Kai Chao, Chih‐Hung Hsu	1
10	Anion-Exchange Blue Perovskite Quantum Dots for Efficient Light-Emitting Devices 2022 ·Nanomaterials ·(unknown), (unknown), Chun‐Cheng Lin, (unknown), Chih‐Hung Hsu, (unknown), Yen‐Ju Chen, Zong‐Liang Tseng	8
11	Deleterious alterations of DNA damage response and repair genes and clinical benefit to anti-PD-1 therapy in esophageal squamous cell carcinoma 2022 ·Esophagus ·(unknown), Chia‐Chi Lin, Chia‐Lang Hsu, (unknown), (unknown), Chen‐Yuan Lin, (unknown), Ann‐Lii Cheng, Chih‐Hung Hsu	0
12	Prognostic value of PD-L1 expression on immune cells or tumor cells for locally advanced esophageal squamous cell carcinoma in patients treated with neoadjuvant chemoradiotherapy 2021 ·Journal of Cancer Research and Clinical Oncology ·(unknown), Cher‐Wei Liang, (unknown), (unknown), Chia‐Chi Lin, (unknown), Ann‐Lii Cheng, Chih‐Hung Hsu	4
13	A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy 2020 ·The Oncologist ·Zhong‐Zhe Lin, Bang‐Bin Chen, Yi‐Ping Hung, (unknown), Ying‐Chun Shen, Yu‐Yun Shao, Chih‐Hung Hsu, Ann‐Lii Cheng, Rheun‐Chuan Lee, Yee Chao, Chiun Hsu	17
14	Phase II study of metabolic response to one-cycle chemotherapy in patients with locally advanced esophageal squamous cell carcinoma 2018 ·Journal of the Formosan Medical Association ·(unknown), Chia‐Chi Lin, Yun‐Chun Wu, Jason Chia‐Hsien Cheng, Jang‐Ming Lee, Hsiu–Po Wang, Pei‐Ming Huang, Feng‐Ming Hsu, Kun‐Huei Yeh, Ann‐Lii Cheng, Kai‐Yuan Tzen, Chih‐Hung Hsu	4
15	Early perfusion changes within 1 week of systemic treatment measured by dynamic contrast-enhanced MRI may predict survival in patients with advanced hepatocellular carcinoma 2016 ·European Radiology ·Bang‐Bin Chen, Chao‐Yu Hsu, Chih‐Wei Yu, Po‐Chin Liang, Chiun Hsu, Chih‐Hung Hsu, Ann‐Lii Cheng, Tiffany Ting‐Fang Shih	17
16	CXCR4 and CXCR6 chemokine receptor-mediated migration and invasion of nasopharyngeal cancer cells are inhibited by Src inhibitors 2014 ·Cancer Research ·Chi‐Long Chen, (unknown), (unknown), Ann‐Lii Cheng, Chih‐Hung Hsu	0
17	Hospital volume of percutaneous radiofrequency ablation is closely associated with treatment outcomes for patients with hepatocellular carcinoma 2012 ·Cancer ·Li‐Chun Lu, Yu‐Yun Shao, (unknown), Zhong‐Zhe Lin, Yi‐Chun Yeh, Wen‐Yi Shau, Chih‐Hung Hsu, Ann‐Lii Cheng, Mei‐Shu Lai	17
18	Inferior Survival of Advanced Pancreatic Cancer Patients Who Received Gemcitabine-Based Chemotherapy but Did Not Participate in Clinical Trials 2011 ·Oncology ·Shih‐Hung Yang, Yu‐Hsuan Kuo, Yu‐Wen Tien, Chiun Hsu, Chih‐Hung Hsu, Sung‐Hsin Kuo, Ann‐Lii Cheng	13
19	Induction Chemotherapy With Gemcitabine, Oxaliplatin, and 5-Fluorouracil/Leucovorin Followed by Concomitant Chemoradiotherapy in Patients With Locally Advanced Pancreatic Cancer: A Taiwan Cooperative Oncology Group Phase II Study 2011 ·International Journal of Radiation OncologyBiologyPhysics ·Hui-Ju Ch’ang, Yulin Lin, Hsiu-Po Wang, (unknown), (unknown), Chih‐Hung Hsu, Yu‐Wen Tien, Jen‐Shi Chen, Ruey‐Kuen Hsieh, Pin-Wen Lin, Yan‐Shen Shan, Ann‐Lii Cheng, Jang‐Yang Chang, Jacqueline Whang‐Peng, Tsann-Long Hwang, Li‐Tzong Chen	19
20	Pseudomelanosis Duodeni: Report of a Case 1998 ·Yow‐Chii Kuo, (unknown), (unknown), Chih‐Hung Hsu	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact